Amgen Quality Chief Retires; Hanley to Succeed
Amgen's chief quality officer steps down at year-end 2026, with the company's vice president of quality taking the role.
Updated on Nov. 3, 2026 in Biotech
Amgen's chief quality officer Jackie Elbonne is retiring at the end of 2026, and Aine Hanley, the company's vice president of quality, will succeed her. The transition is an announced leadership change, not a completed one, and Amgen did not respond to a request for comment.
Why it matters
The change adds to a run of senior departures at Amgen, following former CTO David Reese's June 2026 retirement and former CFO Peter Griffith's August 2026 exit. Quality leadership in biopharma oversees manufacturing and regulatory compliance, so continuity in that role is a reasonable point to watch as the company's executive bench turns over.
The announcement is a personnel disclosure, so the figures are career and tenure data rather than performance metrics. Elbonne's 35 years across seven biopharma companies and Hanley's roughly 14 years at Amgen and Pfizer describe the experience of the incoming and outgoing officers, but the record does not include any quality or manufacturing performance measures.
The players
Amgen
A large American biopharmaceutical company whose portfolio centers on biologic medicines made with recombinant DNA and cell-based manufacturing.
Jackie Elbonne
Amgen's outgoing chief quality officer with 35 years of biopharma experience, previously chief quality officer at Bristol Myers Squibb.
Aine Hanley
Amgen's vice president of quality who will become chief quality officer, with prior service as chief technology officer at Vir Biotechnology.
The details
Chief quality officers in biopharma are responsible for the systems that ensure products are made to regulatory standards. Elbonne previously held the same role at Bristol Myers Squibb and earlier held senior leadership positions at Merck & Co. Hanley, who is taking over, served as chief technology officer at Vir Biotechnology from 2021 to 2025 before rejoining Amgen in 2025.
Timeline
June 2026: Former chief technology officer David Reese retired from Amgen's C-suite.
August 2026: Former chief financial officer Peter Griffith retired from Amgen.
End of 2026: Jackie Elbonne retires as Amgen's chief quality officer, with Aine Hanley succeeding her.
The Tech Race
The change places Amgen's quality function under an executive who has moved between large pharmaceutical companies and a smaller biotech, a path that reflects how biopharma talent circulates among competitors. The succession keeps quality leadership inside the company rather than bringing in an outside hire, which is a different route from the external recruitment common in recent C-suite turnover.
The change affects Amgen's internal quality leadership rather than any product available to patients or users today. No effect on medicine availability, pricing, or regulatory status is stated in the source, and the handover is scheduled to take effect at the end of 2026.
The takeaway
Watch for Amgen to confirm the handover timing and Hanley's scope as chief quality officer ahead of the end-of-2026 transition. Further executive announcements from the company would indicate whether the 2026 retirements are continuing.
Further reading
For broader context on how drugmakers manage their operations, explore the latest Biotech coverage.
Source note: This article includes information reported by FiercePharma.
